This article is more than 5 years old. Information may no longer be current.

VIDEO: Mitro updates Roclatan studies, Aerie financing

ByTom Mitro

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEWPORT BEACH, Calif. ― At the OCTANe Ophthalmology Technology Summit here, Tom Mitro, president and COO of Aerie Pharmaceuticals, discusses the importance of meeting the needs of customers, gives an update on the latest phase 3 studies of Roclatan, which is a combination of Rhopressa and latanoprost, and talks about the company’s latest round of funding.